ClinicalTrials.gg
CompletedNCT00248170FACEUpdated Apr 19, 2016Results posted

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

A Phase 3 interventional study of Letrozole and Anastrozole in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 263 sites in 20 countries. Open to female participants aged 33 Years to 96 Years. Per ClinicalTrials.gov, last updated 2016-04-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,172
Allocation
Randomized
Ages
33 Years to 96 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.

Enrollment
6th of 159
4,172 · median 95
Started
2005
with 10 others
Phase 3
41 of 162
4 open now
Registered
27th of 162
by date
Lead sponsor
21 of 162
Novartis Pharmaceuticals

Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 6th largest by enrollment of the 159 interventional ones that give a count, is one of 11 that started in 2005, is one of 41 in phase 3, and was the 27th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 33 Years to 96 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies testing letrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

Eligible patients will be post-menopausal hormone receptor- and lymph node-positive females who recently underwent primary surgery for breast cancer. Patients will be randomized to letrozole (2.5 mg per day for 5 years) vs anastrozole (1 mg per day for 5 years). Follow up will occur for 5 years after the completion of enrollment for survival and disease status updates.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast cancer
  • letrozole
  • anastrozole
  • adjuvant
  • postmenopausal
  • FACE
04

Who can participate

Ages eligible
33 Years to 96 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recent primary surgery for breast cancer
  • Early stage breast cancer
  • Hormone receptor positive
  • Positive lymph node involvement

Exclusion criteria

Exclusion Criteria:

  • disease
  • Presence of contralateral breast cancer including DCIS
  • Progression

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4,172 participants (actual)

Study arms

  • Experimental
    Letrozole

    2.5 mg by mouth (p.o.) once daily

    Drug: Letrozole

  • Active comparator
    Anastrozole

    1 mg p.o. once daily

    Drug: Anastrozole

Interventions

06

What researchers measure

Primary outcomes

  1. Disease Free Survival

    Disease-free survival was defined as the time from the date of randomization to the date of the first documentation of re-occurrence of invasive breast cancer in local, regional or distant sites, new invasive breast cancer in the contra-lateral breast, or death from any cause.

    Time frame: 84 months

Secondary outcomes

  1. Overall Survival

    Overall survival was defined as the time from the date of randomization to the date of death from any cause.

    Time frame: 84 months

  2. Time to Development of Distant Metastases

    Time to development of distant metastases was defined as the time from date of randomization to the date of the first development of any recurrent or metastatic disease in sites other than the local mastectomy scar, the ipsilateral breast in case of breast conservation or the contra lateral breast.

    Time frame: 84 months

  3. Time to Development of Contra Lateral Breast Cancer

    Time to development of contra lateral breast cancer was defined as the time from the date of randomization to the date of the first development of any disease in the contra lateral breast.

    Time frame: 84 months

  4. Distant Disease-free Survival

    Distant disease-free survival was defined as the time from date of randomization to the date of the first development of any relapse at a distant site or death from any cause.

    Time frame: 84 months

  5. Change From Baseline in Serum Lipid Profiles

    Total cholesterol was analyzed to assess the impact on serum lipids profiles. The adjusted means was calculated.

    Time frame: baseline, 6, 12, 24, 36, 48 and 60 months

  6. Percentage of Participants Who Experienced Clinical Fracture Events

    The incidence of clinical fractures was analyzed.

    Time frame: 84 months

  7. Percentage of Participants Who Experienced Cardiovascular Events

    The incidence of ischemic heart disease, cardiac failures, cerebrovascular accidents and thromboembolic events was analyzed.

    Time frame: 84 months

07

Results

Posted Oct 9, 2015

Participant flow

Participants, who had recently undergone surgery, were randomly assigned in 1:1 ratio to letrozole or anastrozole. Participants received daily treatment until disease recurrence/relapse or for a maximum of 5 years. Participants underwent post-treatment long term follow-up for disease-free survival and overall survival.

Participant flow — Overall Study
MilestoneLetrozoleAnastrozole
Started20782094
Intent-to-treat (itt)20612075
Safety set20492062
Completed13171286
Not completed761808
Withdrew: Withdrawal by subject7179
Withdrew: Protocol violation3530
Withdrew: Lost to follow-up2835
Withdrew: Disease progression196216
Withdrew: Death2847
Withdrew: Adverse event311296
Withdrew: Administrative problems2225
Withdrew: Abnormal test procedure(s) result4961
Withdrew: Abnormal laboratory values40
Withdrew: Protocol deviation1719

Outcome measures

PrimaryDisease Free Survival

Disease-free survival was defined as the time from the date of randomization to the date of the first documentation of re-occurrence of invasive breast cancer in local, regional or distant sites, new invasive breast cancer in the contra-lateral breast, or death from any cause.

Time frame:
84 months
Reported as:
Median · Months
Disease Free Survival
MonthsLetrozoleAnastrozole
Disease Free SurvivalNA (84.14 to NA)NA (NA to NA)
Statistical analysis
  • Letrozole vs Anastrozole · Log Rank · p = 0.3150
SecondaryOverall Survival

Overall survival was defined as the time from the date of randomization to the date of death from any cause.

Time frame:
84 months
Reported as:
Median · Months
Overall Survival
MonthsLetrozoleAnastrozole
Overall SurvivalNA (NA to NA)NA (NA to NA)
SecondaryTime to Development of Distant Metastases

Time to development of distant metastases was defined as the time from date of randomization to the date of the first development of any recurrent or metastatic disease in sites other than the local mastectomy scar, the ipsilateral breast in case of breast conservation or the contra lateral breast.

Time frame:
84 months
Reported as:
Median · Months
Time to Development of Distant Metastases
MonthsLetrozoleAnastrozole
Time to Development of Distant MetastasesNA (84.14 to NA)NA (NA to NA)
SecondaryTime to Development of Contra Lateral Breast Cancer

Time to development of contra lateral breast cancer was defined as the time from the date of randomization to the date of the first development of any disease in the contra lateral breast.

Time frame:
84 months
Reported as:
Median · Months
Time to Development of Contra Lateral Breast Cancer
MonthsLetrozoleAnastrozole
Time to Development of Contra Lateral Breast CancerNA (NA to NA)NA (NA to NA)
SecondaryDistant Disease-free Survival

Distant disease-free survival was defined as the time from date of randomization to the date of the first development of any relapse at a distant site or death from any cause.

Time frame:
84 months
Reported as:
Median · Months
Distant Disease-free Survival
MonthsLetrozoleAnastrozole
Distant Disease-free SurvivalNA (84.14 to NA)NA (NA to NA)
SecondaryChange From Baseline in Serum Lipid Profiles

Total cholesterol was analyzed to assess the impact on serum lipids profiles. The adjusted means was calculated.

Time frame:
baseline, 6, 12, 24, 36, 48 and 60 months
Reported as:
Mean · mg/dL
Change From Baseline in Serum Lipid Profiles
mg/dLLetrozoleAnastrozole
6 months5.643 (5.584 to 5.701)5.553 (5.495 to 5.611)
12 months5.569 (5.510 to 5.629)5.511 (5.452 to 5.570)
24 months5.508 (5.445 to 5.572)5.436 (5.373 to 5.499)
36 months5.429 (5.359 to 5.500)5.427 (5.357 to 5.497)
48 months5.395 (5.323 to 5.468)5.366 (5.293 to 5.438)
60 months5.375 (5.300 to 5.451)5.368 (5.292 to 5.443)
SecondaryPercentage of Participants Who Experienced Clinical Fracture Events

The incidence of clinical fractures was analyzed.

Time frame:
84 months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced Clinical Fracture Events
Percentage of participantsLetrozoleAnastrozole
Percentage of Participants Who Experienced Clinical Fracture Events9.38.1
SecondaryPercentage of Participants Who Experienced Cardiovascular Events

The incidence of ischemic heart disease, cardiac failures, cerebrovascular accidents and thromboembolic events was analyzed.

Time frame:
84 months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced Cardiovascular Events
Percentage of participantsLetrozoleAnastrozole
Ischemic heart disease2.41.5
Cardiac failures1.50.7
Cerebrovascular accidents1.61.5
Thromboembolic events1.21.2

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Letrozole—486/2,049 (23.7%)1,747/2,049 (85.3%)
Anastrozole—520/2,062 (25.2%)1,762/2,062 (85.5%)
Most frequent serious events
Showing 10 of 668
Most frequent serious events
EventLetrozoleAnastrozole
PneumoniaInfections and infestations16/204929/2062
Breast reconstructionSurgical and medical procedures24/204916/2062
OsteoarthritisMusculoskeletal and connective tissue disorders21/204915/2062
Atrial fibrillationCardiac disorders19/204915/2062
FallInjury, poisoning and procedural complications17/204913/2062
Ankle fractureInjury, poisoning and procedural complications14/204910/2062
SyncopeNervous system disorders13/20494/2062
Pulmonary embolismRespiratory, thoracic and mediastinal disorders6/204912/2062
NauseaGastrointestinal disorders11/20496/2062
VomitingGastrointestinal disorders11/20496/2062
Most frequent other events
Showing 10 of 23
Most frequent other events
EventLetrozoleAnastrozole
ArthralgiaMusculoskeletal and connective tissue disorders983/2049983/2062
Hot flushVascular disorders666/2049666/2062
FatigueGeneral disorders345/2049341/2062
MyalgiaMusculoskeletal and connective tissue disorders232/2049211/2062
OsteoporosisMusculoskeletal and connective tissue disorders221/2049224/2062
Back painMusculoskeletal and connective tissue disorders207/2049187/2062
OsteopeniaMusculoskeletal and connective tissue disorders202/2049172/2062
LymphoedemaVascular disorders158/2049177/2062
Pain in extremityMusculoskeletal and connective tissue disorders167/2049174/2062
HeadacheNervous system disorders127/2049164/2062

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LetrozoleAnastrozoleTotal
Mean63.2 ± 8.4863.1 ± 8.4563.2 ± 8.46
Sex/Gender, Customized
Sex/Gender, Customized(Participants)LetrozoleAnastrozoleTotal
Female206120754136
08

Study locations

263 sites
  • Birmingham Hematology and Oncology Associates
    Birmingham, Alabama 35205, United States
  • Comprehensive Cancer Institute
    Huntsville, Alabama 35801, United States
  • Northern Arizona Hematology/Oncology Associates, P.C.
    Flagstaff, Arizona 86001, United States
  • Oncology & Hematology Associates, PC
    New London, Connecticut 06320, United States
  • Florida Cancer Specialists
    Fort Meyers, Florida 33901, United States
  • Sarah Cannon Research Institute
    Jacksonville, Florida 32256, United States
  • Cancer Centers of Florida PA
    Ocoee, Florida 34761, United States
  • Florida Cancer Institute
    Orlando, Florida 32804, United States
  • Gulfcoast Oncology Associates
    St. Petersburg, Florida 33705, United States
  • University Cancer & Blood Center, LLC
    Athens, Georgia 30607, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Kansas City Cancer Center
    Overland Park, Kansas 66210, United States
  • Wichita Community Clinical Oncology Program
    Wichita, Kansas 67214, United States
  • Center for Cancer & Blood Disorders
    Bethesda, Maryland 20817, United States
  • St. Louis Cancer & Breast Institute
    St. Louis, Missouri 63141, United States
  • New York Oncology Hematology, P.C. NYOH Latham
    Troy, New York 12180, United States
  • Raleigh Hematology Oncology Associates
    Cary, North Carolina 27511, United States
  • Aultman Cancer Center
    Canton, Ohio 44710, United States
  • Sarah Cannon Oncology Hematology Care, Inc
    Cincinnati, Ohio 45242, United States
  • Oncology Associates of Oregon, PC
    Eugene, Oregon 97401-8122, United States
  • Medical Oncology Associates of Wyorning Valley, PC
    Kingston, Pennsylvania 18704, United States
  • Chattanooga Oncology and Hematology Assoicates, PC
    Chattanooga, Tennessee 37404, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Texas Oncology, P.A.
    Bedford, Texas 76022, United States
  • Center for Oncology Research and Treatment, PA
    Dallas, Texas 75230, United States
  • Texas Cancer Center ( Medical City Dallas Hospital)
    Dallas, Texas 75230, United States
  • Texas Oncology Presbyterian Hospital
    Dallas, Texas 75246, United States
  • Texas Oncology Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Texas Oncology Texas Oncology PA
    Dallas, Texas 75251, United States
  • Texas Cancer Center Denton
    Denton, Texas 76210, United States
  • El Paso Cancer Treatment Ctr-East
    El Paso, Texas 79915, United States
  • Texas Oncology, P.A.
    Fort Worth, Texas 76104, United States
  • San Antonio Tumor and Blood Clinic
    Fredericksburg, Texas 78624, United States
  • MD Anderson Cancer Center/University of Texas
    Houston, Texas 77030, United States
  • Longview Cancer Center
    Longview, Texas 75601, United States
  • South Texas Cancer Center- McAllen
    McAllen, Texas 78503, United States
  • Allison Cancer Center
    Midland, Texas 79701-5946, United States
  • Texas Cancer Center- Sherman
    Sherman, Texas 75090-0504, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Waco Cancer and Research Center
    Waco, Texas 76712, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Northwest Cancer Specialists, P.C.
    Vancover, Washington 98664, United States
  • Novartis Investigative Site
    Garran, Australian Capital Territory 2605, Australia
  • Novartis Investigative Site
    Port Macquarie, New South Wales 2444, Australia
  • Novartis Investigative Site
    Randwick, New South Wales 2031, Australia
  • Novartis Investigative Site
    Sydney, New South Wales 2060, Australia
  • Novartis Investigative Site
    Tweed Heads, New South Wales 2485, Australia
  • Novartis Investigative Site
    Waratah, New South Wales 2298, Australia
  • Novartis Investigative Site
    Nambour, Queensland 4560, Australia
  • Novartis Investigative Site
    Redcliff, Queensland 4020, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Toorak Gardens, South Australia 5065, Australia
  • Novartis Investigative Site
    Box Hill, Victoria 3128, Australia
  • Novartis Investigative Site
    East Bentleigh, Victoria 3165, Australia
  • Novartis Investigative Site
    Epping, Victoria 3076, Australia
  • Novartis Investigative Site
    Footscray, Victoria 3011, Australia
  • Novartis Investigative Site
    Franston, Victoria 3199, Australia
  • Novartis Investigative Site
    Malvern, Victoria 3144, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
  • Novartis Investigative Site
    Wodonga, Victoria 3690, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    Perth, Western Australia 6000, Australia
  • Novartis Investigative Site
    Perth, Western Australia 6005, Australia
  • Novartis Investigative Site
    Auckland, Australia
  • Novartis Investigative Site
    Dunedin, Australia
  • Novartis Investigative Site
    Hamilton, 3240, Australia
  • Novartis Investigative Site
    Feldkirch, A-6807, Austria
  • Novartis Investigative Site
    Friesach, 9360, Austria
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Graz, A-8036, Austria
  • Novartis Investigative Site
    Güssing, 7540, Austria
  • Novartis Investigative Site
    Innsbruck, 6020, Austria
  • Novartis Investigative Site
    Leoben, A-8700, Austria
  • Novartis Investigative Site
    Linz, 4010, Austria
  • Novartis Investigative Site
    Linz, A-4020, Austria
  • Novartis Investigative Site
    Salzburg, 5020, Austria
  • Novartis Investigative Site
    Vienna, 1090, Austria
  • Novartis Investigative Site
    Villach, 9500, Austria
  • Novartis Investigative Site
    Wels, A-4600, Austria
  • Novartis Investigative Site
    Wiener Neustadt, 2700, Austria
  • Novartis Investigative Site
    Wien, A-1090, Austria
  • Novartis Investigative Site
    Wien, A-1140, Austria
  • Novartis Investigative Site
    Aalst, 9300, Belgium
  • Novartis Investigative Site
    Antwerpen, 2020, Belgium
  • Novartis Investigative Site
    Bonheiden, 2820, Belgium
  • Novartis Investigative Site
    Brasschaat, 2930, Belgium
  • Novartis Investigative Site
    Brugge, 8000, Belgium
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Libramont, 6800, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Liège, 4000, Belgium
  • Novartis Investigative Site
    Turnhout, 2300, Belgium
  • Novartis Investigative Site
    Verviers, 4800, Belgium
  • Novartis Investigative Site
    Wilrijk, 2610, Belgium
  • Novartis Investigative Site
    Newmarket, Ontario L3Y 2P7, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M4C 3E7, Canada
  • Novartis Investigative Site
    Toronto, Ontario M4N 3M5, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada

Showing the first 100 of 263 sites across 20 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2005
First posted
Nov 3, 2005
Start
Dec 2005
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Results first posted
Oct 9, 2015
Last update
Apr 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00248170
Responsible party
Sponsor
First posted
Nov 3, 2005
Start date
Dec 2005
Primary completion
Sep 2014
Completion
Sep 2014
Results posted
Oct 9, 2015
Last update
Apr 19, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion